Heron Therapeutics Inc HRTX
News
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef